DISCLOSURE OF INSIDE INFORMATION PURSUANT TO ART. 17 OF REGULATION (EU) No. 596/2014 (MARKET ABUSE REGULATION) BERLIN, June 9, 2026 /PRNewswire/ -- Pentixapharm Holding AG: FDA grants "Study May Proceed" for PANDA Phase 3 Study; Intended Capital Increase with Subscription Rights in a...
Hence then, the article about pentixapharm holding ag fda grants study may proceed for phase 3 study intended capital increase with subscription rights of up to 10 million shares bafin financial reporting enforcement review of the 2024 consolidated financial statem was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statem )
Also on site :
- I Finally Ordered the Pizza Cupcakes From ‘Shark Tank’—Here’s My Honest Review
- Tech giant OpenAI files for US initial public offering
- I Recreated 5 Viral Y2K Makeup Looks—Here’s What Still Works in 2026